In recent years, there has been an increase in studies regarding delta-catenin’s roles in prostate cancer, with the proposal that delta-catenin may prove to be a therapeutic target (Shrestha et al., 2018; Zhang et al., 2018; Zhou et al., 2019; Li et al., 2020; Shen et al., 2021; Chen et al., 2022). The gene discussed is CTNND2; the disease is Familial prostate cancer.